ReviewInternational journal of general medicine2020
Safety Considerations in Cannabinoid-Based Medicine.
Review in International journal of general medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials.Frontiers in psychiatry · 2022Pooled it
- Effects and safety of a CBD-richFrontiers in pharmacology · 2025Trial
- Questioning assumptions about the abuse potential of medical cannabis and cannabinoids: narrative review and commentary.BJPsych bulletin · 2026Review
- Endocannabinoid system modulation in acute, chronic, and neuropathic pain: reviewing experimental models, clinical evidence, and nanotechnology delivery.Metabolic brain disease · 2026Review
- Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.Psychopharmacology · 2026Review
- Review
- Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes.Cannabis (Albuquerque, N.M.) · 2025Article
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study.Journal of the National Cancer Institute. Monographs · 2024Article
- Article
- Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.Pharmacopsychiatry · 2024Review
- A Descriptive Analysis of Adverse Event Reports from the Quebec Cannabis Registry.Drug safety · 2024Article
- Article
- Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019.JAMA network open · 2023Article
- Article
- Online information on medical cannabis is not always aligned with scientific evidence and may raise unrealistic expectations.Journal of cannabis research · 2022Article
- A Clinical Framework for Assessing Cannabis-Related Impairment Risk.Frontiers in psychiatry · 2022Review
- Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey.Frontiers in neurology · 2022Article
- Inflammaging and Cannabinoids.Ageing research reviews · 2021Review
- Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.Drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabinoids are a diverse class of chemical compounds that are increasingly recognized as potential therapeutic options for a range of conditions. While many studies and reviews of cannabinoids focus on efficacy, safety is much less well reported. Overall assessment of the safety of cannabinoid-based medicines is confounded by confusion with recreational cannabis use as well as different study designs, indications, dosing, and administration methods. However, clinical studies in registered products are increasingly available, and this article aims to discuss and clarify what is known regarding the safety profiles of cannabinoid-based medicines, focusing on the medical and clinical safety evidence and identifying areas for future research. The two most well-studied cannabinoids are Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.